Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

JCO Precis Oncol. 2022 Jun:6:e2100525. doi: 10.1200/PO.21.00525.

Petra Pokorna¹, Giannoula Lakka Klement^{2

3}, Alzbeta Vasikova⁴, Veronika Kanderova⁵, Marta Jezova⁶, Kristyna Noskova^{7

8}, Peter Mudry², Michal Kyr², Tomas Merta², Viera Bajciova², Zdenka Krenova², Hana Palova¹, Dalibor Valik⁹, Lenka Zdrazilova Dubska¹⁰, Ondrej Slaby^{1

11}, Jaroslav Sterba^{2

12}

¹ Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
² Department of Pediatric Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
³ CSTS Health Care, Toronto, ON, Canada.
⁴ Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
⁵ CLIP, Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
⁶ Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
⁷ Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
⁸ Clinical Pharmacy Section of Hospital Pharmacy, University Hospital Brno, Brno, Czech Republic.
⁹ Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
¹⁰ Department of Clinical Microbiology and Immunology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
¹¹ Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
¹² International Clinical Research Center, St Anne's University Hospital, Brno, Czech Republic.

No abstract available

Publication types